Logo image of GLS

GELESIS HOLDINGS INC (GLS) Stock Fundamental Analysis

NYSE:GLS - New York Stock Exchange, Inc. - US36850R2040 - Common Stock - Currency: USD

0.1586  +0 (+0.38%)

After market: 0.1555 0 (-1.95%)

Fundamental Rating

1

GLS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. GLS may be in some trouble as it scores bad on both profitability and health. GLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GLS had negative earnings in the past year.
In the past year GLS has reported a negative cash flow from operations.
GLS Yearly Net Income VS EBIT VS OCF VS FCFGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

GLS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GLS Yearly ROA, ROE, ROICGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 200 400 600 800 1K

1.3 Margins

GLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLS Yearly Profit, Operating, Gross MarginsGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

GLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLS has been increased compared to 1 year ago.
Compared to 1 year ago, GLS has a worse debt to assets ratio.
GLS Yearly Shares OutstandingGLS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 20M 40M 60M
GLS Yearly Total Debt VS Total AssetsGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -8.60, we must say that GLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.60, GLS is not doing good in the industry: 77.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.6
ROIC/WACCN/A
WACC5.71%
GLS Yearly LT Debt VS Equity VS FCFGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 50M -50M

2.3 Liquidity

GLS has a Current Ratio of 0.30. This is a bad value and indicates that GLS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.30, GLS is not doing good in the industry: 94.45% of the companies in the same industry are doing better.
GLS has a Quick Ratio of 0.30. This is a bad value and indicates that GLS is not financially healthy enough and could expect problems in meeting its short term obligations.
GLS's Quick ratio of 0.21 is on the low side compared to the rest of the industry. GLS is outperformed by 94.93% of its industry peers.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.21
GLS Yearly Current Assets VS Current LiabilitesGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

GLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.00%, which is quite impressive.
The Revenue has grown by 80.37% in the past year. This is a very strong growth!
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.08%
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.5%

3.2 Future

Based on estimates for the next years, GLS will show a very strong growth in Earnings Per Share. The EPS will grow by 36.67% on average per year.
GLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 68.56% yearly.
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

GLS Yearly Revenue VS EstimatesGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GLS Yearly EPS VS EstimatesGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLS Price Earnings VS Forward Price EarningsGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLS Per share dataGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as GLS's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GELESIS HOLDINGS INC

NYSE:GLS (4/10/2023, 8:04:01 PM)

After market: 0.1555 0 (-1.95%)

0.1586

+0 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23 2023-03-23/bmo
Earnings (Next)05-10 2023-05-10/bmo
Inst Owners16.44%
Inst Owner Change0%
Ins Owners24.71%
Ins Owner Change0%
Market Cap11.63M
Analysts45
Price Target0.46 (190.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.93%
Min EPS beat(2)41.93%
Max EPS beat(2)41.93%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0.35
BVpS-0.34
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.21
Altman-Z -8.6
F-Score2
WACC5.71%
ROIC/WACCN/A
Cap/Depr(3y)616.89%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.08%
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.5%
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.58%
OCF growth 3YN/A
OCF growth 5YN/A